Please ensure Javascript is enabled for purposes of website accessibility

Why Is Baidu Investing in an AI-Powered Biotech Start-Up?

By Leo Sun – Sep 11, 2020 at 11:56AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Chinese tech giant is seeking investors for a $2 billion investment in a new AI-powered biotech venture.

Chinese tech giant Baidu (BIDU 0.61%) is in talks with interested parties to invest up to $2 billion in a biotech start-up over the next three years, according to Reuters. The company has been incubating the idea over the past six months, and CEO Robin Li is personally overseeing its development.

The start-up, which has yet to be named, will reportedly use Baidu's artificial intelligence (AI) tools to develop new drugs, diagnose tumors, and produce other "biological innovations." Baidu isn't expected to be the controlling shareholder in the new venture.

This wouldn't be Baidu's first step into the AI-powered healthcare market --earlier this year, it open-sourced its RNA prediction algorithm LinearFold to analyze viruses and develop vaccines. But will these new healthcare ventures move the needle for its core business, which still relies heavily on digital ads and its video streaming unit iQiyi (IQ -3.03%)?

A doctor views a patient's body on a transparent screen.

Image source: Getty Images.

Reviewing Baidu's core struggles

Baidu controls over 70% of China's online search market, according to StatCounter. It generates most of its revenue from online ads scattered across its search engine, related portals, and mobile apps.

However, Baidu's ad revenue has declined year over year for five straight quarters due to competition from other ad platforms and the slowdown in China's economic growth. Competition seems to be the more pressing issue, since rival platforms like Tencent's messaging app WeChat, ByteDance's Douyin (known as TikTok overseas), and the anime and gaming platform Bilibili all generated stronger ad revenue growth than Baidu over the past year.

The decline of Baidu's ad business forced the company to rely more heavily on iQiyi, the video streaming unit it spun off in an IPO in 2018, for revenue growth. But iQiyi remains unprofitable -- and the higher mix of iQiyi's revenue is reducing Baidu's margins.

Analysts expect Baidu's revenue to rise less than 1% this year but for cost-cutting measures to boost its earnings by 6%. Those growth rates are anemic compared to Baidu's ecosystem rivals Tencent and Alibaba, which are both expected to generate double-digit revenue and earnings growth this year.

Why is Baidu expanding into digital healthcare?

It might seem odd for Baidu to invest money in AI-powered biotech tools considering the challenges it's facing. However, these investments could expand its broader AI ecosystem -- which already includes its Apollo driverless platform, domestic robotaxis, DuerOS virtual assistant, Xiaodu smart speakers, and various smart city tools and services.

A doctor accesses a patient's data on a tablet.

Image source: Getty Images.

The development of this AI ecosystem could expand Baidu's search engine beyond PCs and mobile devices, which would widen its moat against Tencent, which is pulling away users with WeChat's Mini Programs and integrated searches, and Alibaba, which turned its online marketplaces into China's largest digital advertising platforms.

The COVID-19 crisis also highlighted a growing need for digital upgrades across China's sprawling healthcare system. Tencent-backed WeDoctor, Alibaba's healthcare unit,'s JD Health, and Ping An Good Doctor are all developing various apps for accessing online prescriptions, drug deliveries, medical insurance, appointment bookings, and more to meet those demands.

In that context, it makes sense for Baidu to expand its AI services into the digital healthcare market. That foothold could also convince more digital healthcare companies to launch integrated Mini Programs for the Baidu App -- which competes against WeChat's larger Mini Programs platform.

The key takeaways

Baidu's interest in funding an AI-powered biotech start-up will likely draw comparisons to Alphabet's investments in its life science subsidiaries Calico, which researches treatments for age-related diseases, and Verily, which develops healthcare-related AI services, medical devices, and wearable devices.

But just like Alphabet and its core Google business, Baidu will still generate most of its revenue from online ads for the foreseeable future. Baidu's AI efforts are impressive, especially in the fields of driverless cars and language processing, but they won't generate meaningful revenue or offset its dependence on ads or iQiyi anytime soon.

Suzanne Frey, an executive at Alphabet, is a member of The Motley Fool's board of directors. Leo Sun owns shares of Baidu,, and Tencent Holdings. The Motley Fool owns shares of and recommends Alibaba Group Holding Ltd., Alphabet (A shares), Alphabet (C shares), Baidu, Bilibili,, and Tencent Holdings. The Motley Fool recommends iQiyi. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Baidu, Inc. Stock Quote
Baidu, Inc.
$119.47 (0.61%) $0.72
iQIYI, Inc. Stock Quote
iQIYI, Inc.
$2.88 (-3.03%) $0.09

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/27/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.